Letrozole Tablet, Film Coated
Product Images NDC 51407-986

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 51407-986). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)

Figure-1 (11005a48 13fd 4c6d A024 1e39e3528e45 01)
Chemical structure diagram showing the molecular configuration of Letrozole, the active ingredient in Letrozole Tablets 2.5 mg oral film-coated tablets by Golden State Medical Supply, Inc.*
FDA Label Image

51407-986-90lb Rev. 04-25 .jpg (51407 986 90lb Rev. 04 25)

51407-986-90lb Rev. 04-25 .jpg (51407 986 90lb Rev. 04 25)
Label for Letrozole Tablets USP 2.5 mg, film-coated oral tablets. The label shows the NDC 51407-986-90 and indicates the product contains FD&C Yellow No.5 (tartrazine) as a color additive. Marketed by GSMS, Incorporated, this bottle contains 90 tablets. The label includes storage instructions and a barcode.*
FDA Label Image

Figure-1 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)

Figure-1 (Figure 1 Disease Free Survival Median Follow Up 73 Months Itt Approach)
A line graph titled 'Figure 1 Disease-Free Survival (Median follow-up 73 months, ITT Approach),' depicting disease-free survival probabilities over time (up to 72 months). Two treatments, Letrozole and Tamoxifen, are compared, with Letrozole shown as a solid line and Tamoxifen as a dashed line. The number of patients at risk for each treatment is listed below the x-axis by month. Survival probabilities are plotted on the y-axis from 0.0 to 1.0.*
FDA Label Image

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)

Figure-3 (Figure 2 Kaplan Meier Estimates Of Time To Progression Tamoxifen Study)
A Kaplan-Meier survival curve graph illustrating estimates of time to progression over months. The y-axis shows the progression-free probability, while the x-axis shows time in months. Two treatment groups are compared: Letrozole tablets 2.5 mg and tamoxifen 20 mg, with Letrozole showing a higher progression-free rate over time.*
FDA Label Image

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)

Figure-4 (Figure 3 Survival By Randomized Treatment Arm)
A survival curve chart titled 'Survival by Randomized Treatment Arm' displays the proportion of patients alive over a 60-month period. The solid line represents the letrozole treatment arm, and the dashed line represents the tamoxifen treatment arm. The y-axis shows the fraction alive from 0 to 1, and the x-axis shows time in months.*
FDA Label Image

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)

Figure-5 (Figure 4 Kaplan Meier Estimates Of Time To Progression Megestrol Acetate Study)
A Kaplan-Meier survival curve chart depicting time to progression in days for treatment groups including Letrozole Tablets 0.5 mg, Letrozole Tablets 2.5 mg, and Megestrol Acetate (MA) in a study. The y-axis represents the survival probability, while the x-axis shows the time to progression up to 1000 days.*
FDA Label Image

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)

Figure-6 (Figure 5 Kaplan Meier Estimates Of Time To Progression Amino)
A Kaplan-Meier survival curve chart titled 'Kaplan-Meier Estimates of Time to Progression (Aminoglutethimide Study),' showing curves that compare time to progression in days among three treatment groups: Letrozole Tablets 0.5 mg, Letrozole Tablets 2.5 mg, and AG (aminoglutethimide). The vertical axis shows progression probability from 0 to 1.0, and the horizontal axis displays time to progression in days up to 1000 days.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.